Literature DB >> 25393353

A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer.

Nathalie C Zeitouni1, Ulas Sunar, Daniel J Rohrbach, Anne D Paquette, David A Bellnier, Yi Shi, Gregory Wilding, Thomas H Foster, Barbara W Henderson.   

Abstract

BACKGROUND: Topical photodynamic therapy (PDT) for selected nonmelanoma skin cancer using 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) has yielded high long-term complete response rates with very good cosmesis. Pain during light activation of the photosensitizer can be a serious adverse event. A 2-step irradiance protocol has previously been shown to minimize ALA-PDT pain.
OBJECTIVE: To determine the irradiance-dependent pain threshold for MAL-PDT, to adapt the 2-step protocol to a light-emitting diode (LED) light source, and assess clinical response.
METHODS: In this prospective study, 25 superficial basal cell carcinoma (sBCC) received an initial irradiance by laser at 40 or 50 mW/cm², or LED at 35 mW/cm² followed by an irradiance at 70 mW/cm² for a total of 75 J/cm². Pain levels were recorded for both irradiance steps. Efficacy was assessed at 6, 12, or 24 months.
RESULTS: Pain was mild in the 40/70 mW/cm² laser cohort. Three instances of irradiance-limiting pain occurred at 50/70 mW/cm². Pain was minimal in the 35/70 mW/cm² LED cohort. Clinical response rates were 80% in the 50/70 mW/cm² laser cohort and 90% in the 35/70 mW/cm² LED cohort.
CONCLUSION: Topical PDT can be effectively delivered to sBCC with minimal treatment-related pain by a 2-step irradiance protocol.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25393353      PMCID: PMC4323090          DOI: 10.1097/DSS.0000000000000183

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  28 in total

1.  Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial.

Authors:  I Wang; N Bendsoe; C A Klinteberg; A M Enejder; S Andersson-Engels; S Svanberg; K Svanberg
Journal:  Br J Dermatol       Date:  2001-04       Impact factor: 9.302

2.  Topical photodynamic therapy at low fluence rates--theory and practice.

Authors:  K Langmack; R Mehta; P Twyman; P Norris
Journal:  J Photochem Photobiol B       Date:  2001-04       Impact factor: 6.252

Review 3.  MAL-PDT for difficult to treat nonmelanoma skin cancer.

Authors:  William G Stebbins; C William Hanke
Journal:  Dermatol Ther       Date:  2011 Jan-Feb       Impact factor: 2.851

Review 4.  Photodynamic therapy: current evidence and applications in dermatology.

Authors:  Yoojin Lee; Elma D Baron
Journal:  Semin Cutan Med Surg       Date:  2011-12

5.  Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis.

Authors:  Patrick Gholam; Tanja Weberschock; Katharina Denk; Alexander Enk
Journal:  Dermatology       Date:  2011-07-12       Impact factor: 5.366

6.  Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo.

Authors:  T Dirschka; P Radny; R Dominicus; H Mensing; H Brüning; L Jenne; L Karl; M Sebastian; C Oster-Schmidt; W Klövekorn; U Reinhold; M Tanner; D Gröne; M Deichmann; M Simon; F Hübinger; G Hofbauer; G Krähn-Senftleben; F Borrosch; K Reich; C Berking; P Wolf; P Lehmann; M Moers-Carpi; H Hönigsmann; K Wernicke-Panten; C Helwig; M Foguet; B Schmitz; H Lübbert; R-M Szeimies
Journal:  Br J Dermatol       Date:  2011-12-21       Impact factor: 9.302

7.  Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?

Authors:  Sally H Ibbotson; Ronan Valentine; Ross Hearn
Journal:  Photodermatol Photoimmunol Photomed       Date:  2012-10       Impact factor: 3.135

8.  Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.

Authors:  B W Henderson; T M Busch; L A Vaughan; N P Frawley; D Babich; T A Sosa; J D Zollo; A S Dee; M T Cooper; D A Bellnier; W R Greco; A R Oseroff
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

Review 9.  A review of pain experienced during topical photodynamic therapy--our experience in Dundee.

Authors:  Sasi Kiran Attili; Robert Dawe; Sally Ibbotson
Journal:  Photodiagnosis Photodyn Ther       Date:  2011-02-02       Impact factor: 3.631

10.  A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer.

Authors:  Nathalie C Zeitouni; Anne D Paquette; Joseph P Housel; Yi Shi; Gregory E Wilding; Thomas H Foster; Barbara W Henderson
Journal:  Lasers Surg Med       Date:  2013-02-06       Impact factor: 4.025

View more
  3 in total

1.  Assessing daylight & low-dose rate photodynamic therapy efficacy, using biomarkers of photophysical, biochemical and biological damage metrics in situ.

Authors:  Ana Luiza Ribeiro de Souza; Ethan LaRochelle; Kayla Marra; Jason Gunn; Scott C Davis; Kimberley S Samkoe; M Shane Chapman; Edward V Maytin; Tayyaba Hasan; Brian W Pogue
Journal:  Photodiagnosis Photodyn Ther       Date:  2017-10-14       Impact factor: 3.631

2.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.

Authors:  Jo Ann LeQuang
Journal:  J Clin Aesthet Dermatol       Date:  2017-09-01

Review 3.  Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.

Authors:  Demian van Straten; Vida Mashayekhi; Henriette S de Bruijn; Sabrina Oliveira; Dominic J Robinson
Journal:  Cancers (Basel)       Date:  2017-02-18       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.